Early nonclinical safety studies should provide information to support which item related to first‑in‑human testing?

• A. Initial human dose selection
• B. Post-market pricing
• C. Brand name development
• D. Customer support planning

Answer: (A)

The main idea is that early nonclinical safety data are used to determine the starting dose for the first-in-human trial. By looking at where animals tolerated exposure without adverse effects (the NOAEL) and translating that to a human equivalent dose, with appropriate safety factors to cover species differences and gaps in data, researchers establish a conservative initial dose. This approach, often combined with PK and exposure–response information, helps ensure the first humans aren’t exposed to unsafe levels and guides how doses can be escalated safely in the early phase. The other options—pricing, brand name development, and customer support planning—are business and commercialization tasks and aren’t informed by nonclinical safety findings.